|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC33A1 |
Gene summary for SLC33A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC33A1 | Gene ID | 9197 |
| Gene name | solute carrier family 33 member 1 | |
| Gene Alias | ACATN | |
| Cytomap | 3q25.31 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O00400 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9197 | SLC33A1 | LZE4T | Human | Esophagus | ESCC | 3.16e-13 | 3.74e-01 | 0.0811 |
| 9197 | SLC33A1 | LZE7T | Human | Esophagus | ESCC | 1.28e-02 | 1.36e-01 | 0.0667 |
| 9197 | SLC33A1 | LZE8T | Human | Esophagus | ESCC | 6.01e-06 | 1.71e-01 | 0.067 |
| 9197 | SLC33A1 | LZE21D1 | Human | Esophagus | HGIN | 7.34e-04 | 2.56e-01 | 0.0632 |
| 9197 | SLC33A1 | LZE24T | Human | Esophagus | ESCC | 4.23e-15 | 4.32e-01 | 0.0596 |
| 9197 | SLC33A1 | LZE21T | Human | Esophagus | ESCC | 3.76e-05 | 4.09e-01 | 0.0655 |
| 9197 | SLC33A1 | LZE6T | Human | Esophagus | ESCC | 1.03e-04 | 2.40e-01 | 0.0845 |
| 9197 | SLC33A1 | P1T-E | Human | Esophagus | ESCC | 1.71e-06 | 5.00e-01 | 0.0875 |
| 9197 | SLC33A1 | P2T-E | Human | Esophagus | ESCC | 7.10e-60 | 9.99e-01 | 0.1177 |
| 9197 | SLC33A1 | P4T-E | Human | Esophagus | ESCC | 3.13e-26 | 6.08e-01 | 0.1323 |
| 9197 | SLC33A1 | P5T-E | Human | Esophagus | ESCC | 2.14e-11 | 2.29e-01 | 0.1327 |
| 9197 | SLC33A1 | P8T-E | Human | Esophagus | ESCC | 2.53e-30 | 5.56e-01 | 0.0889 |
| 9197 | SLC33A1 | P9T-E | Human | Esophagus | ESCC | 2.62e-10 | 2.80e-01 | 0.1131 |
| 9197 | SLC33A1 | P10T-E | Human | Esophagus | ESCC | 4.43e-34 | 6.05e-01 | 0.116 |
| 9197 | SLC33A1 | P11T-E | Human | Esophagus | ESCC | 2.19e-09 | 3.08e-01 | 0.1426 |
| 9197 | SLC33A1 | P12T-E | Human | Esophagus | ESCC | 5.92e-15 | 3.34e-01 | 0.1122 |
| 9197 | SLC33A1 | P15T-E | Human | Esophagus | ESCC | 5.85e-19 | 4.12e-01 | 0.1149 |
| 9197 | SLC33A1 | P16T-E | Human | Esophagus | ESCC | 4.36e-28 | 5.82e-01 | 0.1153 |
| 9197 | SLC33A1 | P17T-E | Human | Esophagus | ESCC | 2.92e-05 | 2.59e-01 | 0.1278 |
| 9197 | SLC33A1 | P20T-E | Human | Esophagus | ESCC | 1.43e-17 | 3.81e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001593116 | Esophagus | HGIN | nucleobase-containing compound transport | 57/2587 | 222/18723 | 1.76e-06 | 6.52e-05 | 57 |
| GO:190260017 | Esophagus | HGIN | proton transmembrane transport | 43/2587 | 157/18723 | 5.51e-06 | 1.75e-04 | 43 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
| GO:190260018 | Esophagus | ESCC | proton transmembrane transport | 88/8552 | 157/18723 | 5.62e-03 | 2.10e-02 | 88 |
| GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
| GO:00071789 | Oral cavity | OSCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 165/7305 | 355/18723 | 2.31e-03 | 1.02e-02 | 165 |
| GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC33A1 | SNV | Missense_Mutation | c.781N>T | p.Leu261Phe | p.L261F | O00400 | protein_coding | tolerated(0.08) | benign(0.434) | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR | |
| SLC33A1 | SNV | Missense_Mutation | novel | c.1283T>G | p.Met428Arg | p.M428R | O00400 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC33A1 | SNV | Missense_Mutation | c.1009N>A | p.Glu337Lys | p.E337K | O00400 | protein_coding | deleterious(0.01) | possibly_damaging(0.78) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| SLC33A1 | SNV | Missense_Mutation | novel | c.1619N>T | p.Ser540Leu | p.S540L | O00400 | protein_coding | tolerated(0.34) | benign(0) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| SLC33A1 | SNV | Missense_Mutation | c.559G>A | p.Glu187Lys | p.E187K | O00400 | protein_coding | deleterious(0.03) | benign(0.038) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SLC33A1 | SNV | Missense_Mutation | novel | c.1475N>G | p.Ala492Gly | p.A492G | O00400 | protein_coding | tolerated(0.31) | benign(0.005) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SLC33A1 | SNV | Missense_Mutation | novel | c.65C>T | p.Ser22Phe | p.S22F | O00400 | protein_coding | tolerated_low_confidence(0.16) | benign(0.031) | TCGA-VS-A9UV-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | PD |
| SLC33A1 | SNV | Missense_Mutation | rs767960891 | c.1625N>T | p.Ser542Leu | p.S542L | O00400 | protein_coding | tolerated(0.14) | benign(0.227) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC33A1 | SNV | Missense_Mutation | novel | c.151N>A | p.Ala51Thr | p.A51T | O00400 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SLC33A1 | SNV | Missense_Mutation | c.1565N>G | p.Phe522Cys | p.F522C | O00400 | protein_coding | tolerated(0.08) | benign(0.111) | TCGA-G4-6315-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9197 | SLC33A1 | TRANSPORTER | 178101262 | |||
| 9197 | SLC33A1 | TRANSPORTER | US8592431, 457 | |||
| 9197 | SLC33A1 | TRANSPORTER | US8592431, 181 | |||
| 9197 | SLC33A1 | TRANSPORTER | US8592431, 185 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |